Project Grant R44DK139888
Award Date
9/1/24
Completion Date
6/30/25
Dollars Obligated
$1.1M
Awardee
Makscientific LLC (J2NHTDAJGK24)
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Burlington, MA 01803, USA
Similar Awards
This $675,480 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to develop a novel therapeutic compound for treating chronic kidney disease (CKD). The awardee, Fibrotherapeutics Inc., is conducting preclinical studies to evaluate the efficacy, safety, and therapeutic index of a modified, water-soluble, orally-active peptide derived...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Biotherapeutics, Inc. a $359,625 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports the development of next-generation, once-daily oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes. Key research objectives include evaluating the therapeutic efficacy of the lead drug candidate on lipid metabolism, insulin...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $349,325 Project Grant under CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research to Regennova, Inc., a small disadvantaged business in Durham, North Carolina. The grant supports the development of an orally-available, effective, and well-tolerated drug to treat autosomal dominant polycystic kidney disease (ADPKD), which affects over 350,000 Americans. The project aims to create and...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) is funding research to develop a therapeutic approach using dicarboxylic acids (DCAs) to prevent and treat acute kidney injury (AKI) and limit progression to chronic kidney disease (CKD). The $645,599 award to the University of Pittsburgh is supporting preclinical studies in animal models...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $579,097 Project Grant to The University of Texas MD Anderson Cancer Center. The grant, with a period of performance from July 1, 2025 to March 31, 2030, will fund research to identify and dissect the molecular mechanisms of regulators affecting mitochondrial electron transport chain (ETC) dysfunction in diabetic...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,439,769 project grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Southern California. This 5-year study, titled "PFAS Exposure and Diabetic Kidney Disease in Youth with Type 2 Diabetes: A Multi-Omic Approach for Prevention and Treatment," aims to investigate the link between exposure to per- and polyfluoroalkyl substances...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,712,226 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Orphagen Pharmaceuticals, Inc. The grant supports the development of a novel, first-in-class class of small molecule antagonists that inhibit the gut migration of activated T cells, which is a promising therapeutic approach for treating inflammatory bowel disease (IBD). Preliminary data...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $223,918 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Oklahoma Health Sciences Center. The purpose of this 20-month grant, awarded on September 28, 2024, is to study niche filling as a means to achieve long-term, kidney-specific depletion of resident macrophages in order to slow the progression of autosomal dominant polycystic...
The U.S. Department of Health and Human Services' National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $361,400 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Oncotrap Inc. The funding supports the development of a bispecific single-domain antibody targeting the chemokines CCL2 and CCL5 for the treatment of non-alcoholic steatohepatitis (NASH). The award will enable Oncotrap to generate a human version...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $436,277 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Delaware. The grant titled "NEPHROGENESIS ON A CHIP: AN SIMPLE MODULAR PLATFORM TO SPATIALLY PATTERN EXTRACELLULAR MATRIX, STROMAL CELLS, AND SOLUBLE FACTORS" aims to develop an easy-to-use 3D in vitro model of the developing nephron that allows spatial patterning...